Merck (MRK) and LaNova Medicines, a privately held clinical-stage biotechnology company, announced that Merck has entered into an exclusive ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

Merck KGaA CFO Helene von Roeder discusses the group's third-quarter earnings and its progress with drug trials.

Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate ...

(Bloomberg) -- Merck KGaA posted earnings that topped estimates as its ... That’s better than the €1.56 billion average of ...

The life-sciences and chemical group said it now expects 2024 net sales in the lower half of its previously expected range of ...

The diversified group has suffered high-profile setbacks in late-stage drug trials, prompting it to halt development of head ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that Canada's Drug Agency (CDA) has ...

Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

Bristol Myers Squibb (NYSE: BMY) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

Ripple effects from Polsinelli's 47-lawyer group move this summer are still generating benefits for the firm on the lateral ...